The company is developing an early autism detection and treatment platform
LinusBio, a 2021 spinoff company from Mount Sinai, announced it raised over $16 million in Series A venture capital funding to deliver a novel platform that bridges genomics, the environment, and biological response. The company’s platform is based on new methods and technology developed by scientists at the Institute for Exposomic Research at Mount Sinai.
“Our mission is simple: to enable better outcomes to people and families affected by complex health conditions,” said Manish Arora, PhD, Director of the Institute for Exposomic Research Laboratories at Mount Sinai, and Co-Founder and CEO of LinusBio.
Historically, many diseases have had no biological testing that’s been available in medical practice for diagnosis, monitoring the progression of disease, or for providing molecular endpoints in clinical trials. Dr. Arora and his team aim to introduce precision exposome biomarkers that can facilitate discovery across many diseases – everything from autism to gastrointestinal disorders to amyotrophic lateral sclerosis (ALS) to renal disease and cancers.
“We chose to focus on autism first for many considerations, an important one of them is the dramatically different trajectory in case of an early detection and effective intervention,” said Arora.
“The impact on the patient and the patient’s family can be substantial.”